FI945426L - GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn - Google Patents

GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn Download PDF

Info

Publication number: FI945426L
Authority: FI; Finland
Prior art keywords: gaba; glutamic acid; acid analogues; seizure treatment; seizure
Prior art date: 1992-05-20

Application number

FI945426A

Other languages

English (en)

Swedish (sv)

Other versions

FI945426A0 (fi

FI945426A7 (fi

Inventor

Richard B Silverman

Ryszard Andruszkiewicz

Po-Wai Yuen

Denis Martin Sobieray

Lloyd Charles Franklin

Mark Alan Schwindt

Original Assignee

Univ Northwestern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-20

Filing date

1993-05-18

Publication date

1994-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI945426(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-05-18 Application filed by Univ Northwestern filed Critical Univ Northwestern

1994-11-18 Publication of FI945426A0 publication Critical patent/FI945426A0/fi

1994-11-18 Publication of FI945426A7 publication Critical patent/FI945426A7/fi

1994-11-18 Publication of FI945426L publication Critical patent/FI945426L/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Enzymes And Modification Thereof (AREA)

FI945426A 1992-05-20 1993-05-18 GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn FI945426L (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88608092A	1992-05-20	1992-05-20
PCT/US1993/004680 WO1993023383A1 (en)	1992-05-20	1993-05-18	Gaba and l-glutamic acid analogs for antiseizure treatment

Publications (3)

Publication Number	Publication Date
FI945426A0 FI945426A0 (fi)	1994-11-18
FI945426A7 FI945426A7 (fi)	1994-11-18
FI945426L true FI945426L (fi)	1994-11-18

Family

ID=25388336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI945426A FI945426L (fi)	1992-05-20	1993-05-18	GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn

Country Status (21)

Country	Link
EP (1)	EP0641330B1 (fi)
JP (2)	JP3856816B2 (fi)
KR (1)	KR950701625A (fi)
AT (1)	ATE207052T1 (fi)
AU (1)	AU677008B2 (fi)
CA (1)	CA2134674C (fi)
CZ (1)	CZ286106B6 (fi)
DE (2)	DE69330949T2 (fi)
DK (1)	DK0641330T3 (fi)
ES (1)	ES2165857T3 (fi)
FI (1)	FI945426L (fi)
HU (2)	HU222776B1 (fi)
LU (1)	LU91112I2 (fi)
NL (1)	NL300164I2 (fi)
NO (1)	NO944370L (fi)
NZ (1)	NZ253459A (fi)
PT (1)	PT641330E (fi)
RU (2)	RU94046105A (fi)
SG (1)	SG48288A1 (fi)
SK (1)	SK283281B6 (fi)
WO (1)	WO1993023383A1 (fi)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
PL187064B1 (pl) *	1994-07-27	2004-05-31	Warner Lambert Co	Zastosowania gabapentyny do leczenia i/lub zapobiegania stanom lękowym
US5792796A (en) *	1994-07-27	1998-08-11	Warner-Lambert Company	Methods for treating anxiety and panic
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) *	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh)	1996-07-24	2002-11-27	沃尼尔·朗伯公司	用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
CA2263663C (en) *	1996-10-23	2006-05-30	Justin Stephen Bryans	Substituted gamma aminobutyric acids as pharmaceutical agents
WO1999008670A1 (en)	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
BR9812162A (pt)	1997-09-08	2000-07-18	Warner Lambert Co	Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
EP1077692B1 (en) *	1998-05-15	2004-07-28	Warner-Lambert Company LLC	Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
CA2344407C (en) *	1998-10-16	2007-01-09	Warner-Lambert Company	Method for the treatment of mania and bipolar disorder
AU1602100A (en)	1998-11-25	2000-06-13	Warner-Lambert Company	Improved gamma amino butyric acid analogs
TR200102837T2 (tr) *	1999-04-08	2002-03-21	Warner-Lambert Company	ídrar tutamama durumunun tedavisi
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
US6642398B2 (en)	1999-06-10	2003-11-04	Warner-Lambert Company	Mono-and disubstituted 3-propyl gamma-aminobutyric acids
EA004398B1 (ru) *	1999-06-10	2004-04-29	Уорнер-Ламберт Компани	Одно- и двузамещенные 3-пропил-гамма-аминомасляные кислоты
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
AU2002213422A1 (en)	2000-09-13	2002-03-26	Georgetown University	Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
US6992076B2 (en)	2000-10-06	2006-01-31	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en)	2000-10-06	2003-11-19	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
RU2202538C2 (ru) *	2001-05-04	2003-04-20	Савельев Евгений Александрович	Способ получения 4-аминомасляной кислоты
US6462084B1 (en) *	2001-05-14	2002-10-08	Brookhaven Science Associates, Llc	Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) *	2001-06-11	2012-01-15	Xenoport Inc	Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
WO2002100344A2 (en)	2001-06-11	2002-12-19	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6927036B2 (en)	2002-02-19	2005-08-09	Xero Port, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
RU2220131C2 (ru) *	2002-02-28	2003-12-27	Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации"	Соли 4-амино-3-фенилбутановой кислоты и лекарственное средство, обладающие антиишемической гипотензивной, противоаритмической, ноотропной и антигипоксической активностью
WO2003080588A1 (en)	2002-03-20	2003-10-02	Xenoport	Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US20030225149A1 (en)	2002-04-30	2003-12-04	Blazecka Peter G.	Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
WO2003099338A2 (en)	2002-05-17	2003-12-04	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en)	2002-08-29	2006-07-04	Warner Lambert Company Llc	Process for preparing functionalized γ-butyrolactones from mucohalic acid
AU2003297927A1 (en)	2002-12-11	2004-06-30	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
PT1572173E (pt)	2002-12-13	2010-05-10	Warner Lambert Co	Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
NZ540591A (en) *	2002-12-13	2008-03-28	Warner Lambert Co	Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2537837A1 (en)	2003-09-11	2005-03-24	Xenoport, Inc.	Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
CA2537402C (en)	2003-09-12	2009-05-05	Pfizer Inc.	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CN1871021B (zh)	2003-09-17	2010-07-28	什诺波特有限公司	用gaba类似物的前药治疗或预防多动腿综合征
NZ546381A (en)	2003-10-14	2010-01-29	Xenoport Inc	Crystalline form of gamma-aminobutyric acid analog
PL1691811T3 (pl)	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
RU2440112C2 (ru)	2004-11-04	2012-01-20	Ксенопорт, Инк.	Пероральная дозированная форма габапентина замедленного высвобождения
EP1820502A1 (en)	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising azolylcarbinol compounds
CN101600458A (zh)	2006-12-22	2009-12-09	瑞蔻达蒂爱尔兰有限公司	采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
CA2710152A1 (en) *	2007-12-26	2009-07-02	Generics (Uk) Limited	Processes to pregabalin
US7868043B2 (en)	2008-01-25	2011-01-11	Xenoport, Inc.	Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
JP5291123B2 (ja)	2008-01-25	2013-09-18	ゼノポート，インコーポレイティド	（３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
US7872046B2 (en)	2008-01-25	2011-01-18	Xenoport, Inc.	Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2110372A1 (en)	2008-04-16	2009-10-21	Chemo Ibérica, S.A.	Intermediates for the preparation of Pregabalin and process for their preparation
EP2116539A1 (en)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2123626A1 (en)	2008-05-21	2009-11-25	Laboratorios del Dr. Esteve S.A.	Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP2344447B1 (en)	2008-10-08	2016-06-08	Xgene Pharmaceutical Inc	Gaba conjugates and methods of use thereof
RU2393855C1 (ru) *	2008-12-29	2010-07-10	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Средство, обладающее анксиолитической и церебропротекторной активностью, уменьшающее влечение к алкоголю
ES2362913B1 (es)	2009-12-24	2012-05-24	Moehs Iberica S.L.	Nuevo método para la preparación de (s)-pregabalina.
EP2353598A1 (en)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
HUE035072T2 (en) *	2010-03-18	2018-05-02	Daiichi Sankyo Co Ltd	Cycloalkyl substituted imidazole derivative
EP2548872B1 (en)	2010-03-18	2016-09-28	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
EP2383255A1 (en)	2010-04-28	2011-11-02	Lacer, S.A.	New compounds, synthesis and use thereof in the treatment of pain
EP2388005A1 (en)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
AU2011283462B9 (en)	2010-07-30	2014-09-18	Toray Industries, Inc.	Therapeutic agent or prophylactic agent for neuropathic pain
EP2415460A1 (de)	2010-08-03	2012-02-08	ratiopharm GmbH	Orale Darreichungsform von Pregabalin
EP2415471A1 (en)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in opioid-induced hyperalgesia
US8212072B2 (en)	2010-08-13	2012-07-03	Divi's Laboratories, Ltd.	Process for the preparation of pregabalin
EP2524694A1 (en)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in diabetes type-2 associated pain
EP2527319A1 (en)	2011-05-24	2012-11-28	Laboratorios Del. Dr. Esteve, S.A.	Crystalline forms of pregabalin and co-formers in the treatment of pain
WO2013100873A1 (en)	2011-12-19	2013-07-04	Mahmut Bilgic	Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
ES2423254B1 (es)	2012-02-15	2014-03-26	Laboratec, S.L.	Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
EP2948139B1 (en)	2013-01-28	2019-06-12	Lopez, Hector, L.	Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105873578A (zh)	2013-12-17	2016-08-17	埃斯蒂维实验室股份有限公司	血清素－去甲肾上腺素再摄取抑制剂(SNRIs)和σ受体配体组合物
CN105873580B (zh)	2013-12-17	2020-08-25	埃斯蒂维制药有限公司	加巴喷丁类化合物与σ受体配体的组合物
WO2016075082A1 (en)	2014-11-10	2016-05-19	Sandoz Ag	Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
CA3099775A1 (en)	2018-05-14	2019-11-21	Xgene Pharmaceutical Inc.	Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
DE202018105573U1 (de)	2018-09-27	2018-10-19	Laboratec	Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis
AU2022210509A1 (en)	2021-01-22	2023-08-17	Egis Gyógyszergyár Zrt.	Topical formulation containing dispersed pregabalin
HU231397B1 (hu)	2021-01-22	2023-06-28	Egis Gyógyszergyár Zrt.	Pregabalint tartalmazó topikális gyógyszerkészítmény

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4840460B1 (fi) *	1969-02-05	1973-11-30
US4173541A (en) *	1978-06-05	1979-11-06	Cincinnati Milacron Chemicals Inc.	Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) *	1980-06-25	1982-03-30	New York University	Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) *	1982-12-16	1984-10-23	The Dow Chemical Company	Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) *	1986-01-21	1988-09-13	Ici Americas Inc.	Hydroxamic acids
US4814342A (en) *	1986-10-31	1989-03-21	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) *	1990-10-19	1993-05-14	한국과학기술연구원	d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
AU9137091A (en) *	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) *	1992-01-30	1993-03-30	Warner-Lambert Company	Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

1993
- 1993-05-18 HU HU9702482A patent/HU222776B1/hu active IP Right Grant
- 1993-05-18 SK SK1395-94A patent/SK283281B6/sk not_active IP Right Cessation
- 1993-05-18 DE DE69330949T patent/DE69330949T2/de not_active Expired - Lifetime
- 1993-05-18 RU RU94046105/04A patent/RU94046105A/ru unknown
- 1993-05-18 NZ NZ253459A patent/NZ253459A/en not_active IP Right Cessation
- 1993-05-18 ES ES93925173T patent/ES2165857T3/es not_active Expired - Lifetime
- 1993-05-18 KR KR1019940704158A patent/KR950701625A/ko not_active Withdrawn
- 1993-05-18 DK DK93925173T patent/DK0641330T3/da active
- 1993-05-18 EP EP93925173A patent/EP0641330B1/en not_active Expired - Lifetime
- 1993-05-18 AU AU43794/93A patent/AU677008B2/en not_active Ceased
- 1993-05-18 CA CA002134674A patent/CA2134674C/en not_active Expired - Lifetime
- 1993-05-18 PT PT93925173T patent/PT641330E/pt unknown
- 1993-05-18 JP JP50380794A patent/JP3856816B2/ja not_active Expired - Lifetime
- 1993-05-18 WO PCT/US1993/004680 patent/WO1993023383A1/en not_active Ceased
- 1993-05-18 RU RU96124481A patent/RU2140901C1/ru active
- 1993-05-18 AT AT93925173T patent/ATE207052T1/de active
- 1993-05-18 DE DE1993630949 patent/DE122004000039I2/de active Active
- 1993-05-18 HU HU9403310A patent/HU222339B1/hu active Protection Beyond IP Right Term
- 1993-05-18 FI FI945426A patent/FI945426L/fi not_active Application Discontinuation
- 1993-05-18 SG SG1996008718A patent/SG48288A1/en unknown
- 1993-05-18 CZ CZ19942849A patent/CZ286106B6/cs not_active IP Right Cessation
1994
- 1994-11-16 NO NO944370A patent/NO944370L/no unknown
2004
- 2004-03-16 JP JP2004075406A patent/JP4297814B2/ja not_active Expired - Lifetime
- 2004-10-06 LU LU91112C patent/LU91112I2/fr unknown
- 2004-11-22 NL NL300164C patent/NL300164I2/nl unknown

Also Published As

Publication number	Publication date
HU222339B1 (hu)	2003-06-28
HUT71522A (en)	1995-12-28
WO1993023383A1 (en)	1993-11-25
PT641330E (pt)	2002-03-28
EP0641330A1 (en)	1995-03-08
HU9702482D0 (en)	1998-03-02
JP3856816B2 (ja)	2006-12-13
RU94046105A (ru)	1997-06-20
HU9403310D0 (en)	1995-02-28
CZ284994A3 (en)	1995-03-15
FI945426A0 (fi)	1994-11-18
NL300164I1 (nl)	2005-01-03
DE69330949D1 (de)	2001-11-22
CZ286106B6 (cs)	2000-01-12
AU4379493A (en)	1993-12-13
FI945426A7 (fi)	1994-11-18
HK1011022A1 (en)	1999-07-02
DK0641330T3 (da)	2001-12-03
AU677008B2 (en)	1997-04-10
EP0641330B1 (en)	2001-10-17
LU91112I2 (fr)	2004-12-06
SG48288A1 (en)	1998-04-17
RU2140901C1 (ru)	1999-11-10
DE69330949T2 (de)	2002-04-04
EP0641330A4 (en)	1997-05-28
SK139594A3 (en)	1995-05-10
SK283281B6 (sk)	2003-05-02
NZ253459A (en)	1997-03-24
NL300164I2 (nl)	2005-02-01
NO944370D0 (no)	1994-11-16
ES2165857T3 (es)	2002-04-01
CA2134674A1 (en)	1993-11-25
JP4297814B2 (ja)	2009-07-15
KR950701625A (ko)	1995-04-28
CA2134674C (en)	2004-12-21
DE122004000039I1 (de)	2006-05-18
NO944370L (no)	1994-11-21
JPH07508288A (ja)	1995-09-14
ATE207052T1 (de)	2001-11-15
HU222776B1 (hu)	2003-10-28
JP2004238398A (ja)	2004-08-26
DE122004000039I2 (de)	2006-06-29

Publication	Publication Date	Title
FI945426A7 (fi)	1994-11-18	GABA- ja L-glutamiinihappoanalogit kohtauksenvastaiseen käsittelyyn
AU9137091A (en)	1992-06-25	Gaba and l-glutamic acid analogs for antiseizure treatment
DK42093D0 (da)	1993-04-07	Administrationsmetode
FI962249A7 (fi)	1996-05-29	Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
FI971991A7 (fi)	1997-05-09	2-syaaniakryylihappoesterit
FI955133A7 (fi)	1995-10-27	Jäteveden käsittelyprosessi ja laite
DE69424640D1 (de)	2000-06-29	Filmbehandlungsmethode und System
BR9507166A (pt)	1997-09-09	Conjunto de dentes para tratamento de uma superfície
FI930656A7 (fi)	1993-08-25	Nasaalihoitoon tarkoitettu koostumus
DE69325487D1 (de)	1999-08-05	Bild Prozessor und Verfahren
KR950700707A (ko)	1995-02-20	치과용 치료시스템
FI971750A7 (fi)	1997-06-24	Koostumuksia multippeliskleroosia varten ja sen hoito
FI922582L (fi)	1992-12-06	Fettsyrabehandling
FR2723093B1 (fr)	1997-12-12	Esters d'acyle d'acides amines achiraux du glanciclovir
FI20010045L (fi)	2001-01-10	Syklopentaani- ja penteeni-beta-aminohapot
FI943847A7 (fi)	1995-02-24	Menetelmä ja laite nestemäisen hapen pumppaamiseksi
DE69330813D1 (de)	2001-10-31	Bildprozessor und verfahren dafuer
FI960425L (fi)	1996-08-02	Fenyylisykloheksyylikarboksyylihappoamidien käyttö
NO930722L (no)	1993-09-14	Imidazolylsubstituerte fenyleddiksyreamider
DK0606333T3 (da)	1997-09-22	Afsvovlingsbehandling
NO982463D0 (no)	1998-05-29	Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
DE69605918D1 (de)	2000-02-03	Salpetersäure-hydrolyse von polyamiden
DE59301768D1 (de)	1996-04-11	Zahnbehandlungseinheit
NO974651D0 (no)	1997-10-08	Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
DE69311802D1 (de)	1997-07-31	Verfahren zur metallbehandlung

Legal Events

Date	Code	Title	Description
1995-12-08	FD	Application lapsed